Standard of Care and Disease Management

At this time, there is no approved enzyme replacement therapy (ERT) or disease-modifying treatment for Galactosialidosis that has been authorized by the FDA or EMA ^[1][2]. Because there is no “cure” or way to replace the missing protein yet, the goal of medical care is supportive management.

Supportive management means your doctors will focus on treating individual symptoms as they arise to improve quality of life and prevent complications ^[2]. This approach requires a multidisciplinary team—a group of different specialists working together to watch over every system in the body ^[3].

Managing the Body Systems

Because Galactosialidosis affects many organs, care is broken down into several specific areas:

• Heart Health (Cardiology): Doctors monitor for changes such as thickening of the heart muscle (ventricular hypertrophy) or issues with the heart valves (regurgitation) ^[2][3]. Regular heart ultrasounds (echocardiograms) and EKGs may be recommended as part of an individualized surveillance plan ^[2].
• Kidney and Fluid Management (Renal): Your team will check for protein in the urine (proteinuria) or swelling in the kidneys (hydronephrosis) ^[4]. They also monitor for ascites (fluid buildup in the belly), which can require specialized care if it becomes severe enough to affect breathing ^[5]. Ascites may also reflect underlying cardiac, hepatic, or renal disease.
• Bone and Spine (Orthopedics): Skeletal changes, such as a curved spine (scoliosis), short stature, and dysostosis multiplex, are commonly reported ^[3]. Care may include physical therapy, bracing, or orthopedic surgery to maintain mobility and manage pain ^[2].
• Vision (Ophthalmology): Regular eye exams are needed to monitor for cherry-red spots in the retina, lens clouding (cataracts), and changes in the cornea that can affect sight ^[6].
• Movement and Brain (Neurology): If sudden muscle jerks (myoclonus) or balance issues (ataxia) occur, neurologists may consider various medications—such as levetiracetam or clonazepam—to help reduce these symptoms ^[7][8]. (Note: Any medication for myoclonus must be carefully selected by a specialist, as some can cause sedation or suppress breathing—a serious risk for those with airway vulnerability. Do not start or stop these medications without consulting your neurologist.)

Daily Needs and Additional Support

Supportive care goes beyond organ scans. It is critical to assess needs for:

• Feeding and Swallowing: Evaluation by a speech-language pathologist for safe swallowing and nutrition, especially if choking occurs.
• Respiratory Surveillance: Monitoring for sleep-disordered breathing or sleep apnea.
• Therapies: Physical, occupational, and speech therapy for mobility and communication.
• Mental Health and Palliative Care: Emotional support for patients and caregivers, and supportive-care clinicians when appropriate to maximize comfort and quality of life.

A Note on Anesthesia Safety

One of the most important parts of day-to-day management is planning for any surgery or procedure. Galactosialidosis can cause unique changes to the airway and abdomen (due to ascites) that make anesthesia more dangerous ^[9]. Always ensure an anesthesiologist is aware of this diagnosis well in advance of any procedure, as they may need to take special precautions when helping a patient wake up and breathe on their own after surgery ^[9].

The Research Horizon

While no treatment is available for human use today, scientists are actively working on future options in the laboratory. It is important to know that these are currently in the preclinical stage, meaning they have only been tested in animal models (like mice) or human cells in a lab ^[10]. They do not establish human safety or efficacy, and you should not attempt to obtain unapproved experimental products outside of a properly governed clinical trial.

• Enzyme Replacement Therapy (ERT): Researchers have developed a lab-made version of the PPCA protein. In mouse studies, regular injections of this enzyme helped reduce the buildup of sialylated oligosaccharides in the brain and other organs ^[10][11].
• Gene Therapy: This approach uses a harmless virus (AAV) to deliver a healthy copy of the CTSA gene into the liver. In mice, a single treatment allowed the liver to produce the missing protein for up to a year, which was then “shared” with other organs, including the brain ^[12].
• Chaperone Therapy: Some small molecules (like NOEV) are being studied to see if they can help the body’s existing enzymes work a little better, though this research is still in early cellular stages ^[13].